BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
Study Details
Study Description
Brief Summary
RATIONALE: BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. BL22 immunotoxin may be effective in treating relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
PURPOSE: This phase I trial is studying the side effects and best dose of BL22 immunotoxin in treating young patients with relapsed or refractory acute lymphoblastic leukemia or non-Hodgkin's lymphoma.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1 |
Detailed Description
OBJECTIVES:
Primary
-
Determine the toxic effects of BL22 immunotoxin in pediatric patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia or non-Hodgkin's lymphoma.
-
Determine the maximum tolerated dose of this drug in these patients.
-
Determine the immunogenicity of this drug in these patients.
-
Determine the pharmacokinetics of this drug in these patients.
Secondary
-
Determine the in vitro cytotoxicity of this drug against lymphoblasts from patients with acute lymphoblastic leukemia.
-
Determine the therapeutic efficacy of this drug in inducing remissions in these patients.
-
Determine changes in lymphocyte subsets, immunoglobulin levels, serum cytokines, and soluble cytokine receptor levels in patients treated with this drug.
OUTLINE: This is a non-randomized, dose-escalation study.
Patients receive BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses.
Cohorts of 3-6 patients receive escalating doses of BL22 immunotoxin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, the cohort is expanded and a total of 12 patients are treated at that dose.
Patients are followed weekly for at least 1 month and then every 1-3 months thereafter.
PROJECTED ACCRUAL: A total of 95 patients will be accrued for this study.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: 1 BL22 immunotoxin |
Drug: BL22 immunotoxin
BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses.
|
Active Comparator: 2 antibody therapy |
Procedure: antibody-drug conjugate therapy
CD22 antibody, RFB4 on day 7
|
Active Comparator: 3 immunotoxin therapy |
Procedure: immunotoxin therapy
tested for immunogenicity to CAT-8015 before each cycle and at end of study.
|
Active Comparator: 4 monoclonal antibody therapy |
Procedure: monoclonal antibody therapy
administered intravenously over 30 minutes.
|
Outcome Measures
Primary Outcome Measures
- assessment of efficacy, safety, pharmacokinetics, immunogenicity. [end of study]
Secondary Outcome Measures
- Expansion of MTD [end of study]
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Histologically confirmed acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma (including lymphoblastic lymphoma, Burkitt's lymphoma, and large cell lymphoma)
-
Not amenable to available curative therapies
-
Relapsed or refractory disease after at least 1 standard chemotherapy and 1 salvage regimen
-
CD22 positive according to at least 1 of the following criteria:
-
More than 15% CD22-positive malignant cells by immunohistochemistry
-
More than 30% CD22-positive malignant cells by fluorescent-activated cell sorter analysis
-
Measurable or evaluable disease
-
Prior CNS involvement allowed provided there is no current evidence of CNS malignancy
-
No CNS leukemia or lymphoma as manifested by any of the following:
-
Cerebrospinal fluid (CSF) WBC ≥ 5/mm^3 and confirmation of CSF blasts
-
Cranial neuropathies secondary to underlying malignancy
-
Radiologically detected CNS lymphoma
-
No isolated testicular ALL
-
Ineligible for or refused hematopoietic stem cell transplantation OR has disease activity that prohibits the time required to identify a suitable stem cell donor
PATIENT CHARACTERISTICS:
Age
- 6 months to 24 years
Performance status
-
ECOG 0-3 (12 to 24 years of age)
-
Lansky 40-100% (under 12 years of age)
Life expectancy
- Not specified
Hematopoietic
-
See Disease Characteristics
-
Absolute neutrophil count > 1,000/mm^3 *
-
Platelet count > 50,000/mm^3 * NOTE: *Non-leukemic patients only
Hepatic
-
Bilirubin ≤ 2.0 mg/dL
-
AST and ALT ≤ 5 times upper limit of normal
-
No active hepatitis B or C infection
Renal
-
Creatinine normal for age OR
-
Creatinine clearance ≥ 60 mL/min
Immunologic
-
No serum neutralization of more than 75% of the activity of 1 µg/mL of study drug
-
HIV negative
Other
-
Not pregnant or nursing
-
Negative pregnancy test
-
Fertile patients must use effective contraception
-
No clinically significant unrelated systemic illness that would preclude study participation
-
No other significant organ dysfunction that would preclude study participation
-
No psychiatric illness or social situation that would preclude study compliance
PRIOR CONCURRENT THERAPY:
Biologic therapy
-
See Disease Characteristics
-
At least 1 week since prior colony-stimulating factors (e.g., filgrastim [G-CSF], sargramostim [GM-CSF], or epoetin alfa)
-
Prior autologous or allogeneic hematopoietic stem cell transplantation (HSCT) allowed
-
More than 100 days since prior allogeneic HSCT
Chemotherapy
-
See Disease Characteristics
-
At least 2 weeks since prior chemotherapy (6 weeks for nitrosoureas)
Endocrine therapy
-
Concurrent corticosteroids allowed provided there has been no increase in the dose 1 week prior to and after study entry
-
Steroid taper allowed
Radiotherapy
-
At least 3 weeks since prior radiotherapy
-
Allowed in the past 3 weeks provided the volume of the bone marrow treated is < 10% AND the patients has measurable disease outside of the radiation port
Surgery
- Not specified
Other
-
Recovered from prior therapy
-
At least 30 days since prior investigational drugs
-
No other concurrent investigational drugs
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office | Bethesda | Maryland | United States | 20892-1182 |
Sponsors and Collaborators
- MedImmune LLC
- Cambridge Antibody Technology
Investigators
- Principal Investigator: Alan S. Wayne, MD, National Cancer Institute (NCI)
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CDR0000352020
- NCI-04-C-0079H
- NCI-5643
- NCT00075309